Original Article

Correlation of Heterozygote risk, Pathological risk and lifetime risk with Clinicopathologic Features in Iranian breast cancer patients

Sahar Ardalan, Mahtab Dastpak, Fatemeh Homayee Shandiz, Narjes Forouzanfar, Ariane Sadr-Nabavi

Sahar Ardalan
Medical Genetic Research Center (MGRC), School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Mahtab Dastpak
Academic Center for Education, Culture, and Research (ACECR)-Khorasan Razavi, Mashhad, Iran

Fatemeh Homayee Shandiz
Department of Radiation Oncology, Cancer Research Center, Mashhad University of Medical Sciences, Iran

Narjes Forouzanfar
Academic Center for Education, Culture, and Research (ACECR)-Khorasan Razavi, Mashhad, Iran

Ariane Sadr-Nabavi
Medical Genetic Research Center (MGRC), School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Email: sadrnabavia@mums.ac.ir
Online First: June 30, 2017 | Cite this Article
Ardalan, S., Dastpak, M., Homayee Shandiz, F., Forouzanfar, N., Sadr-Nabavi, A. 2017. Correlation of Heterozygote risk, Pathological risk and lifetime risk with Clinicopathologic Features in Iranian breast cancer patients. The Cancer Press 3(2): 67-73. DOI:10.15562/tcp.45


Breast cancer is a prevalent malignancy among women worldwide and a principle reason of death in Iranian women. In current study, 64 Iranian women diagnosed with breast cancer and classified into four age groups (<35 years, 35–49 years, 50–64 years and >65 years) were analyzed for correlation between heterozygote risk and lifetime risk with clinicopathological features. Nine patients were also investigated for BRCA1 germline mutations. Our results indicated that people with hetrozygosity risk over 30% more likely to infect invasive ductal carcinoma and utilization of Cyrillic software for Iranian family would open new sights towards the prediction, prognosis and mutation detection.
Article Views      : 239
PDF Downloads : 117